Can Coronary Plaque Shrink? Soft Plaque vs. Hard Plaque—and Why Your Calcium Score Can Rise on a Statin

The short answer

Yes, coronary plaque can shrink—but usually modestly, and not all plaque behaves the same way. Intensive LDL-cholesterol lowering can reduce plaque burden and help stabilize plaques. At the same time, statins can increase the density of calcium within plaque, causing a coronary artery calcium (CAC) score to rise.

That sounds contradictory. It isn't necessarily.

A rising calcium score during statin treatment does not automatically mean your arteries are getting worse. But it also doesn't prove that your plaque is harmless or that your risk has disappeared.

Soft plaque vs. hard plaque: What's the difference?

Atherosclerosis develops when cholesterol, inflammatory cells, connective tissue and other material accumulate in artery walls. Over time, plaques can develop different compositions.

Noncalcified plaque contains little or no detectable calcium. Some noncalcified plaques contain a large lipid-rich core and a thin protective cap. These features can make a plaque more vulnerable to rupture. However, not all noncalcified plaque is dangerous, and a scan cannot determine risk from the word “soft” alone.

Calcified plaque contains calcium deposits. Dense calcium can be associated with a more stable plaque structure, particularly when treatment changes plaque composition. But calcified plaque is still evidence of coronary atherosclerosis. It does not mean the artery is normal, nor does it guarantee that a plaque cannot cause problems.

Plaque vulnerability depends on several features—including its size, composition, inflammation and cap structure—not simply whether it is soft or hard.

Can coronary plaque actually shrink?

Yes. Research using coronary imaging has shown that intensive cholesterol-lowering treatment can produce modest reductions in plaque volume.

The GLAGOV clinical trial, for example, found that adding the LDL-lowering drug evolocumab to statin therapy produced greater regression of coronary atherosclerosis than statin therapy alone. Other imaging studies have also found reductions in total plaque volume with intensive statin treatment.

But regression is not the same as erasing disease. Plaque may shrink somewhat, change composition or become more stable while substantial atherosclerosis remains.

The goal of treatment is to reduce the likelihood of heart attack and other cardiovascular events—not to make every imaging measurement return to zero.

Why can a calcium score rise on a statin?

A CAC score measures the amount and density of detectable calcium in coronary artery plaque. It does not directly measure all plaque, the size of the artery opening or blood flow through the artery.

Statins lower LDL cholesterol and reduce cardiovascular risk. They can also change the composition of plaque. Imaging research suggests that statin treatment can reduce some lipid-rich, lower-attenuation plaque while increasing the density of calcified plaque.

Because the Agatston calcium score incorporates both the area and density of calcium, denser calcium can contribute to a higher score—even when treatment is having beneficial effects on plaque composition.

This is an important distinction: a higher CAC score during statin treatment does not necessarily mean treatment has failed.

However, the opposite conclusion would also be a mistake. A rising score cannot, by itself, establish that plaque has stabilized, that total plaque burden has fallen or that an individual's risk is lower.

What does the latest guidance say?

The 2026 ACC/AHA dyslipidemia guideline notes that statin therapy often increases CAC scores, even while treatment may stabilize or reduce plaque volume and improve clinical outcomes. It states that routine repeat CAC testing is not indicated once lipid-lowering therapy has been initiated.

That makes sense because CAC is primarily a tool for assessing coronary atherosclerosis and helping guide preventive treatment—not a reliable way to monitor whether statins are working.

A calcium score also cannot tell you whether a particular narrowing is restricting blood flow. That question may require a different form of assessment, depending on the person's symptoms, history and clinical circumstances.

If CAC isn't the right way to monitor treatment, what matters?

More useful questions include:

• Is LDL cholesterol sufficiently low? The appropriate target depends on the person's overall cardiovascular risk.
• Is ApoB adequately controlled? ApoB can help estimate the number of atherogenic particles in circulation.
• Are medications being taken consistently and tolerated?
• Are blood pressure, smoking, diabetes, exercise and other risk factors being addressed?
• Have symptoms or functional abilities changed? New chest discomfort, unusual breathlessness or a decline in exercise tolerance deserves medical assessment.

A clinician may recommend additional testing when symptoms, functional status or other clinical findings change. Repeating scans simply to see whether the calcium score has increased is generally not a useful way to judge statin effectiveness.

What should you do if your score rises?

Don't stop or reduce a prescribed statin solely because your CAC score has increased. Discuss the result with your healthcare professional in the context of your LDL and ApoB levels, treatment history, symptoms and overall cardiovascular risk.

A high CAC score remains evidence of substantial coronary atherosclerosis, even when cholesterol levels are excellent and treatment is working. And a reassuring stress test, while useful in the right context, does not erase the information provided by a high calcium burden.

The right interpretation depends on the whole clinical picture—not one number in isolation.

Evidence Assessment: STRONG

Evidence strongly supports intensive LDL lowering to reduce cardiovascular risk and supports the finding that statins can alter plaque composition while increasing coronary calcium density. Evidence also supports the limitation of CAC scoring as a tool for monitoring treatment response.

Important limitation: A change in calcium density cannot determine an individual's plaque stability or establish whether their total plaque burden has improved. Imaging studies and population-level findings do not guarantee the same response in every person.